FIGURE 3.

Reporting rate^a of SAEs by MedDRA System Organ Class in the PMS data for tofacitinib in patients with UC and RA^b. Post‐marketing exposure to tofacitinib based on estimated worldwide sales, was 8916 patient‐years for patients with UC and 34 223 patient‐years for patients with RA. MedDRA, Medical Dictionary for Regulatory Activities; NR, not reported at the time of analysis; PMS, post‐marketing surveillance; RA, rheumatoid arthritis; SAE, serious adverse event; UC, ulcerative colitis. ^aReporting rate is calculated by dividing the number of SAEs per MedDRA System Organ Class by the estimated patient‐years of exposure (per 100 patient‐years). ^bAs reported by Cohen et al. ¹⁰